[Influence of topically applied iodides on urinary iodine excretion and thyroid function].

Purpose: The present study was undertaken, to evaluate whether ophthalmic drug, containing iodine applied to conjunctival sac might result in a significant increase of urine iodine excretion and thus might be indirectly associated with the risk of iodine-induced hyperthyroidism. The aim of the study was to examine the occurrence of biochemically relevant changes in urine iodine excretion and in thyroid function after topical administration of ophthalmic drug containing iodine.

Material And Methods: In the study twenty-two patients without a history of thyroid disease were examined.

[Evaluation of the relationship between chosen factors and results of whole body scintigraphy with 131I in patients with differentiated thyroid cancers].

Treatment and diagnostics with 131I play an important role in patients with differentiated thyroid cancer (DTC) after thyreoidectomy. The aim of the study was to assess the influence of some factors on ablative therapy results. Fifty seven patients with DTC were investigated (44 females--mean age 46.

[Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].

The aim of the study was to evaluate radiation risk in the environment of patients treated with 131I as an ablative therapy following radical surgery for the differentiated thyroid cancer. The activities of radioiodine used in this form of therapy approximate 2.8 GBq (76 mCi) and the in cases of the cancer metastases to other organs may be as high as 7.

[Problems with radiation protection for adjuvant radiotherapy of thyroid cancer].

Ablative treatment of thyroid cancer with 131I is associated with the exposure to ionizing radiation of not only the target cells but also other cells and organs in the patient's body. Thermoluminescent dosimetry showed that the mean dose equivalent in ovaries equaled to several dozen mSv when the mean therapeutic dose was 2.8 GBq of 131I.